Detection of ganciclovir resistance after valacyclovir-prophylaxis in renal transplant recipients with active cytomegalovirus infection

被引:31
作者
Alain, S
Hantz, S
Scieux, C
Karras, A
Mazeron, MC
Szelag, JC
Imbert, BM
Fillet, AM
Gouarin, S
Mengelle, C
de Wilde, A
Cogne, N
Champier, G
Rogez, S
Legendre, C
Denise, F
机构
[1] Teaching Hosp Dupuytren, Dept Bacteriol Virol Hyg, EA, Limoges, France
[2] Teaching Hosp St Louis, Dept Nephrol, Paris, France
[3] Teaching Hosp St Louis, Dept Bacteriol Virol, Paris, France
[4] Teaching Hosp Lariboisiere, Dept Bacteriol Virol, Paris, France
[5] Teaching Hosp Dupuytren, Dept Nephrol, Limoges, France
[6] Teaching Hosp, Dept Virol, Nantes, France
[7] Teaching Hosp Pitie Salpetriere, Dept Virol, Paris, France
[8] Teaching Hosp Caen, Caen, France
[9] Teaching Hosp Purpan, Dept Virol, Toulouse, France
[10] Teaching Hosp Lille, Dept Virol, Lille, France
关键词
human cytomegalovirus; ganciclovir resistance; valaciclovir transplantation;
D O I
10.1002/jmv.20127
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Whether valaciclovir(VCV) prophylaxis could be responsible for ganciclovir (GCV)-resistance of Human cytomegalovirus (HCMV) in transplantation has never been documented. A multicentric retrospective pilot study was undertaken to detect GCV-resistance through mutations within the UL97 gene in renal transplant recipients who experienced active HCMV infection and received valacyclovir prophylaxis. Twenty-three patients who experienced HCMV antigenaemia or DNAemia during or at the end of prophylaxis were included. UL97 genotyping was carried out on peripheral blood samples, using a nested in-house PCR, which amplified the full-length UL97 gene. One patient has a resistance-related mutation (M4601); the major risk factor for emergence of resistance in this patient was the presence of early and persistent antigenaemia. GCV-resistance during VCV-prophylaxis was rare after renal transplantation. However, special attention must be paid to patients developing early active HCMV infection under prophylaxis. (C) 2004 Wiley-Liss, Inc.
引用
收藏
页码:566 / 573
页数:8
相关论文
共 22 条
[11]   High incidence of ganciclovir-resistant cytomegalovirus infection among lung transplant recipients receiving preemptive therapy [J].
Limaye, AP ;
Raghu, G ;
Koelle, DM ;
Ferrenberg, J ;
Huang, ML ;
Boeckh, M .
JOURNAL OF INFECTIOUS DISEASES, 2002, 185 (01) :20-27
[12]   Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants [J].
Limaye, AP ;
Corey, L ;
Koelle, DM ;
Davis, CL ;
Boeckh, M .
LANCET, 2000, 356 (9230) :645-649
[13]   Randomized study of valacyclovir as prophylaxis against cytomegalovirus reactivation in recipients of allogeneic bone marrow transplants [J].
Ljungman, P ;
de la Camara, R ;
Milpied, N ;
Volin, L ;
Russell, CA ;
Crisp, A ;
Webster, A .
BLOOD, 2002, 99 (08) :3050-3056
[14]   Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation [J].
Lowance, D ;
Neumayer, HH ;
Legendre, CM ;
Squifflet, JP ;
Kovarik, J ;
Brennan, PJ ;
Norman, D ;
Mendez, R ;
Keating, MR ;
Coggon, GL ;
Crisp, A ;
Lee, IC .
NEW ENGLAND JOURNAL OF MEDICINE, 1999, 340 (19) :1462-1470
[15]   Analysis and characterization of antiviral drug-resistant cytomegalovirus isolates from solid organ transplant recipients [J].
Lurain, NS ;
Bhorade, SM ;
Pursell, KJ ;
Avery, RK ;
Yeldandi, VV ;
Isada, CM ;
Robert, ES ;
Kohn, DJ ;
Arens, MQ ;
Garrity, ER ;
Taege, AJ ;
Mullen, MG ;
Todd, KM ;
Bremer, JW ;
Yen-Lieberman, B .
JOURNAL OF INFECTIOUS DISEASES, 2002, 186 (06) :760-768
[16]   Sequencing of cytomegalovirus UL97 gene for genotypic antiviral resistance testing [J].
Lurain, NS ;
Weinberg, A ;
Crumpacker, CS ;
Chou, SW .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (10) :2775-2780
[17]  
Michel D, 2001, J MED VIROL, V65, P70
[18]   Valaciclovir - A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in herpesvirus infections [J].
Perry, CM ;
Faulds, D .
DRUGS, 1996, 52 (05) :754-772
[19]   Herpes simplex virus DNA in corneal transplants: Prospective study of 38 recipients [J].
Robert, PY ;
Adenis, JP ;
Denis, F ;
Alain, S ;
Ranger-Rogez, S .
JOURNAL OF MEDICAL VIROLOGY, 2003, 71 (01) :69-74
[20]   The economic value of valacyclovir prophylaxis in transplantation [J].
Squifflet, JP ;
Legendre, C .
JOURNAL OF INFECTIOUS DISEASES, 2002, 186 :S116-S122